Central liver cancer surgical resection of 35 cases Patients who died. Among them, AFP was positive in 27 cases and postoperative AFP turned negative in all these cases. After 1 year, the 3-year and 5-year survival rates were 82.1%, 59.5% and 39.3%, respectively. Complications: Postoperative bile leakage occurred in four cases, six cases had right pleural effusion, and subphrenic effusion occurred in two cases, all of which were cured by conservative treatment. Among 33 cases of hepatocellular carcinoma, a complete capsule surrounded the tumor in 4 cases, the capsule was incomplete or absent in 9 cases, and there were two cases of cholangiocarcinoma with a complete capsule. No cancer cell invasion was found at the liver resection margin. Discussion 3.1 Surgical options for liver cancer patients with hepatitis, cirrhosis, hepatic functional reserve, and taste generation, hemi-liver or extended hemi-liver resection usually results in postoperative liver failure. A too small range of liver resection may leave lesions that cause early intrahepatic recurrence after surgery. In this group of patients, the tumor diameter was more than 5 cm in 12 cases (34.29%). The preoperative three-dimensional reconstruction of CT lesions and B-ultrasound positioning during surgery were performed. Among the 35 patients, 24 cases (68.57%) underwent single liver segment or sub-hepatic segment resection, combined with hepatic resection in 4 cases (11.43%), local resection in 1 case (0.03%), irregular, totaling 82.86% of the cases. Hemi-liver or extended semi-six cases of liver resection, accounting for 17.14% of the total number of cases. There was no operative mortality, and no serious complications occurred after surgery. After 1 year, 3 years, and 5 years, the survival rate of surgical treatment is better. Flexibly selecting liver sections and combined liver segment resection under the assistance of various new technologies is the future trend for central type liver cancer. Three-dimensional reconstruction of preoperative CT and intraoperative B-ultrasound auxiliary positioning in three-dimensional graphics of central type liver cancer patients before CT is feasible for multi-plane reconstruction in various ways, clearly showing the bile duct, portal vein, and hepatic venous system. It can clearly observe the anatomical relationship between the lesion and surrounding vasculature, whether there is vascular invasion and metastasis, assess surgical resectability, and help choose a favorable surgical approach. B-ultrasound-assisted positioning technique provides accurate diagnosis of liver lesions, combining with preoperative CT three-dimensional reconstruction, it can find the extent, borders, vascular invasion, and small spread of the tumor, also guiding surgical resection and implementing anatomy. For patients with a tumor diameter of more than 5 cm, preoperative CT lesion reconstruction combined with intraoperative B-ultrasound-assisted positioning did not result in large vessel and bile duct injury during surgery, successfully completing the surgery at the porta hepatis first. Postoperative pathological examination showed no cancer cell invasion at the liver resection margin. The average time for the porta hepatis was 460ml, and the average bleeding time was 19 minutes, showing no significant difference compared to conventional liver resection surgery. Skilled application of imaging techniques aid can effectively improve liver resection and avoid leaving lesions in central type liver cancer patients before surgery. Liver resection of central liver cancer in clinical practice is a high-risk surgery, based on the surgeon’s skills and tips from imaging of the liver cancer site, the relationship of the intrahepatic main structure, metastasis, and accurate judgment of the function of the right hepatic decompensation, and multi-mode RF, microwave ablation therapy, such as surgical resection, have reduced the operative mortality rate to a lower level. Preoperative CT three-dimensional reconstruction and intraoperative B-ultrasound assisted positioning will help improve the therapeutic effect of central type liver cancer and reduce the incidence of complications.